Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Recent guidance from the Food and Drug Administration for the evaluation of new therapies in the treatment of type 2 diabetes (T2DM) calls for a program-wide meta-analysis of cardiovascular (CV) outcomes. In this context, we develop a new Bayesian meta-analysis approach using survival regression models to assess whether the size of a clinical development program is adequate to evaluate a particular safety endpoint. We propose a Bayesian sample size determination methodology for meta-analysis clinical trial design with a focus on controlling the type I error and power. We also propose the partial borrowing power prior to incorporate the historical survival meta data into the statistical design. Various properties of the proposed methodology are examined and an efficient Markov chain Monte Carlo sampling algorithm is developed to sample from the posterior distributions. In addition, we develop a simulation-based algorithm for computing various quantities, such as the power and the type I error in the Bayesian meta-analysis trial design. The proposed methodology is applied to the design of a phase 2/3 development program including a noninferiority clinical trial for CV risk assessment in T2DM studies.

[1]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[2]  Joseph G Ibrahim,et al.  Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.

[3]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[4]  David B. Wolfson,et al.  Bayesian Sample Size Determination for Binomial Proportions , 2008 .

[5]  Fulvio De Santis,et al.  Using historical data for Bayesian sample size determination , 2007 .

[6]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[7]  D. Rubin.  Bayesianly Justifiable and Relevant Frequency Calculations for the Applied Statistician , 1984 .

[8]  Nicola J Cooper,et al.  Evidence‐based sample size calculations based upon updated meta‐analysis , 2007, Statistics in medicine.

[9]  Fei Wang,et al.  A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models , 2002 .

[10]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[11]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[12]  Donald A. Berry,et al.  Relationship Between Bayesian and Frequentist Sample Size Determination , 2005 .

[13]  George E. P. Box,et al.  Sampling and Bayes' inference in scientific modelling and robustness , 1980 .

[14]  Jesse A Berlin,et al.  Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team , 2009, Clinical trials.